Head-To-Head Comparison: PetVivo (OTCMKTS:PETV) and Boston Scientific (NYSE:BSX)
Head-To-Head Comparison: PetVivo (OTCMKTS:PETV) and Boston Scientific (NYSE:BSX)
Boston Scientific (NYSE:BSX – Get Rating) and PetVivo (OTCMKTS:PETV – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.
波士頓科學公司(NYSE：BSX-GET Rating)和PetVivo(OTCMKTS：PETV-GET Rating)都是醫療公司，但哪隻股票更好？我們將根據兩家公司的股息、風險、機構所有權、收益、分析師建議、估值和盈利能力來比較它們的實力。
Analyst Ratings
分析師評級
This is a summary of recent ratings and recommmendations for Boston Scientific and PetVivo, as reported by MarketBeat.com.
據MarketBeat.com報道，這是波士頓科學公司和PetVivo公司最近的評級和推薦摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Boston Scientific | 0 | 1 | 10 | 1 | 3.00 |
| PetVivo | 0 | 0 | 1 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 波士頓科學公司 | 0 | 1 | 10 | 1 | 3.00 |
| PetVivo | 0 | 0 | 1 | 0 | 3.00 |
Boston Scientific currently has a consensus price target of $46.55, indicating a potential upside of 13.11%. PetVivo has a consensus price target of $7.00, indicating a potential upside of 178.88%. Given PetVivo's higher possible upside, analysts plainly believe PetVivo is more favorable than Boston Scientific.
波士頓科學公司目前的共識目標價為46.55美元，表明潛在上行幅度為13.11%。PetVivo的一致目標價為7美元，表明潛在漲幅為178.88%。考慮到PetVivo更有可能的上行空間，分析師們顯然認為PetVivo比波士頓科學公司更有利。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Boston Scientific | 7.16% | 14.58% | 7.60% |
| PetVivo | -3,817.65% | -99.68% | -82.24% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 波士頓科學公司 | 7.16% | 14.58% | 7.60% |
| PetVivo | -3,817.65% | -99.68% | -82.24% |
Insider & Institutional Ownership
內部人與機構所有權
90.5% of Boston Scientific shares are held by institutional investors. Comparatively, 13.7% of PetVivo shares are held by institutional investors. 0.7% of Boston Scientific shares are held by company insiders. Comparatively, 35.3% of PetVivo shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
波士頓科學公司90.5%的股份由機構投資者持有。相比之下，PetVivo 13.7%的股份由機構投資者持有。波士頓科學公司0.7%的股份由公司內部人士持有。相比之下，PetVivo 35.3%的股份由公司內部人士持有。強大的機構持股表明，捐贈基金、對衝基金和大型基金管理公司相信，一家公司的長期表現將好於大盤。
Valuation and Earnings
估值和收益
This table compares Boston Scientific and PetVivo's top-line revenue, earnings per share (EPS) and valuation.
該表格比較了波士頓科學公司和PetVivo的營收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Boston Scientific | $11.89 billion | 4.95 | $1.04 billion | $0.58 | 70.95 |
| PetVivo | $120,000.00 | 209.96 | -$5.01 million | ($0.75) | -3.35 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 波士頓科學公司 | 118.9億美元 | 4.95 | 10.4億美元 | $0.58 | 70.95 |
| PetVivo | $120,000.00 | 209.96 | -501萬元 | ($0.75) | -3.35 |
Boston Scientific has higher revenue and earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
波士頓科學公司的收入和收益比PetVivo更高。PetVivo的市盈率低於波士頓科學公司，這表明它目前是兩隻股票中更負擔得起的一隻。
Volatility & Risk
波動性與風險
Boston Scientific has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, PetVivo has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500.
Boston Science的貝塔係數為0.85，表明其股價的波動性比標準普爾500指數低15%。相比之下，PetVivo的貝塔係數為1.96，這表明其股價的波動性比標準普爾500指數高96%。
Summary
摘要
Boston Scientific beats PetVivo on 10 of the 14 factors compared between the two stocks.
波士頓科學公司在比較兩隻股票的14個因素中有10個超過了PetVivo。
About Boston Scientific
關於波士頓科學公司
(Get Rating)
(獲取評級)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
波士頓科學公司開發、製造和營銷醫療設備，用於世界各地的各種介入醫學專科。它通過三個部分運作：Medsurg，Rhythm and Neuro和心血管。該公司提供診斷和治療胃腸道和肺部疾病的設備；治療各種泌尿和盆腔疾病的設備；植入式心臟復律和植入式心臟再同步治療除顫器；起搏器和植入式心臟再同步治療起搏器；以及遠程患者管理系統。它還提供診斷和治療心臟頻率和節律紊亂的醫療技術，包括3D心臟標測和導航解決方案、消融導管、診斷導管、標測導管、心內超聲導管、分娩鞘和其他附件；用於治療慢性疼痛的脊髓刺激器系統；間接減壓系統；以及腦深部刺激系統。此外，該公司還提供介入心臟病學產品，包括用於治療冠狀動脈疾病的藥物洗脱冠狀動脈支架系統；用於治療動脈粥樣硬化的經皮冠狀動脈介入產品；用於冠狀動脈和心腔以及各種外周血管的血管內導管定向超聲成像導管、部分血流儲備設備和系統；以及結構性心臟治療。此外，它還提供用於治療動脈疾病的支架、球囊導管、導線和動脈粥樣硬化系統；用於治療靜脈疾病的血栓切除和聲學脈衝溶栓系統、導線和支架；用於治療癌症的外周栓塞器、放射性微球、消融系統、冷凍治療消融系統以及微型和引流導管。該公司成立於1979年，總部設在馬爾伯勒。, 馬薩諸塞州。
About PetVivo
關於PetVivo
(Get Rating)
(獲取評級)
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
PetVivo控股公司是一家生物醫療設備公司，從事用於治療動物疾病和疾病的醫療設備和生物材料的製造、商業化和許可。它的主要產品是Spryng，一種由獸醫管理的關節內注射，用於治療跛行和其他關節疾病，如狗和馬的骨關節炎。該公司的流水線產品還包括17種用於獸醫和人類臨牀應用的治療設備。PetVivo控股公司成立於2009年，總部設在明尼蘇達州明尼阿波利斯市。
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
接受《波士頓科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對波士頓科學公司及相關公司評級的每日簡要摘要。